Efficacy of BI 1356 compared to placebo in patients for whom metformin therapy is
inappropriate (intolerability, contraindication). The second part of the study looks at the
safety of BI 1356 in this patient population with longer term treatment in comparison to a
sulfonylurea drug (glimepiride)
Minimum age: 18 Years.
Maximum age: 80 Years.
Gender(s): Both.
1218.50.52007 Boehringer Ingelheim Investigational Site, Aguascalientes, Mexico
1218.50.52010 Boehringer Ingelheim Investigational Site, Guadalajara, Mexico
1218.50.52009 Boehringer Ingelheim Investigational Site, León, Mexico
1218.50.52002 Boehringer Ingelheim Investigational Site, Mexico, Mexico
1218.50.52008 Boehringer Ingelheim Investigational Site, Mexico, Mexico
1218.50.52001 Boehringer Ingelheim Investigational Site, Monterrey, Mexico
1218.50.52003 Boehringer Ingelheim Investigational Site, Monterrey, Mexico
1218.50.52004 Boehringer Ingelheim Investigational Site, México, Mexico
1218.50.52005 Boehringer Ingelheim Investigational Site, México, Mexico
1218.50.63003 Boehringer Ingelheim Investigational Site, Cebu, Philippines
1218.50.63005 Boehringer Ingelheim Investigational Site, Cebu, Philippines
1218.50.63006 Boehringer Ingelheim Investigational Site, Manila, Philippines
1218.50.63008 Boehringer Ingelheim Investigational Site, Manila, Philippines
1218.50.63001 Boehringer Ingelheim Investigational Site, Marikina, Philippines
1218.50.63004 Boehringer Ingelheim Investigational Site, Marikina, Philippines
1218.50.63007 Boehringer Ingelheim Investigational Site, Pasay, Philippines
1218.50.63002 Boehringer Ingelheim Investigational Site, Pasig, Philippines
1218.50.63009 Boehringer Ingelheim Investigational Site, Pasig, Philippines
1218.50.40004 Boehringer Ingelheim Investigational Site, Brasov, Romania
1218.50.40001 Boehringer Ingelheim Investigational Site, Bucharest, Romania
1218.50.40002 Boehringer Ingelheim Investigational Site, Bucharest, Romania
1218.50.40005 Boehringer Ingelheim Investigational Site, Galati, Romania
1218.50.40003 Boehringer Ingelheim Investigational Site, Sibiu, Romania
1218.50.70001 Boehringer Ingelheim Investigational Site, Moscow, Russian Federation
1218.50.70003 Boehringer Ingelheim Investigational Site, Moscow, Russian Federation
1218.50.70002 Boehringer Ingelheim Investigational Site, St. Petersburg, Russian Federation
1218.50.70004 Boehringer Ingelheim Investigational Site, St. Petersburg, Russian Federation
1218.50.70005 Boehringer Ingelheim Investigational Site, St. Petersburg, Russian Federation
1218.50.38002 Boehringer Ingelheim Investigational Site, Kharkiv, Ukraine
1218.50.38001 Boehringer Ingelheim Investigational Site, Kiev, Ukraine
1218.50.38004 Boehringer Ingelheim Investigational Site, Kiev, Ukraine
1218.50.38003 Boehringer Ingelheim Investigational Site, Lvov, Ukraine
1218.50.38005 Boehringer Ingelheim Investigational Site, Vinnitsa, Ukraine
1218.50.10009 Boehringer Ingelheim Investigational Site, Birmingham, Alabama, United States
1218.50.11001 Boehringer Ingelheim Investigational Site, Edmonton, Alberta, Canada
1218.50.11003 Boehringer Ingelheim Investigational Site, Edmonton, Alberta, Canada
1218.50.10011 Boehringer Ingelheim Investigational Site, Peoria, Arizona, United States
1218.50.10013 Boehringer Ingelheim Investigational Site, Greenbrae, California, United States
1218.50.10016 Boehringer Ingelheim Investigational Site, Harbor City, California, United States
1218.50.10017 Boehringer Ingelheim Investigational Site, Huntington Park, California, United States
1218.50.10006 Boehringer Ingelheim Investigational Site, Los Angeles, California, United States
1218.50.10007 Boehringer Ingelheim Investigational Site, Miami, Florida, United States
1218.50.10004 Boehringer Ingelheim Investigational Site, Statesville, North Carolina, United States
1218.50.11005 Boehringer Ingelheim Investigational Site, Sarnia, Ontario, Canada
1218.50.10002 Boehringer Ingelheim Investigational Site, Eugene, Oregon, United States
1218.50.11002 Boehringer Ingelheim Investigational Site, Montague, Prince Edward Island, Canada
1218.50.11004 Boehringer Ingelheim Investigational Site, Saskatoon, Saskatchewan, Canada
1218.50.10015 Boehringer Ingelheim Investigational Site, Greer, South Carolina, United States
1218.50.10005 Boehringer Ingelheim Investigational Site, Kingsport, Tennessee, United States
1218.50.10012 Boehringer Ingelheim Investigational Site, Dallas, Texas, United States
1218.50.10022 Boehringer Ingelheim Investigational Site, Dallas, Texas, United States
1218.50.10010 Boehringer Ingelheim Investigational Site, San Antonio, Texas, United States
1218.50.10018 Boehringer Ingelheim Investigational Site, San Antonio, Texas, United States